PharmaPendium - An introduction June 2012

26
Welcome to our PharmaPendium Webinar! PharmaPendium, for informed drug development decisions Your host: Dianne Baunbaek Your presenter: Pooja Jain An introduction

description

During our 45-minute webinar, Pooja Jain outlines the following:- How your peers are using Pharmapendium to successfully move drugs along the pipeline.- How you can be “Better informed” and what this really means to you and your colleagues.

Transcript of PharmaPendium - An introduction June 2012

Page 1: PharmaPendium - An introduction June 2012

Welcome to our PharmaPendium Webinar!

PharmaPendium, for informed drug development decisions

Your host: Dianne Baunbaek Your presenter: Pooja Jain

An introduction

Page 3: PharmaPendium - An introduction June 2012

Webinar control panel:

‘chat’ or ‘ask a question’ for questions

and comments

Option for full screen view

Q&A after presentation

Need to know

Page 4: PharmaPendium - An introduction June 2012

4

Today’s Agenda

What is PharmaPendium?

How do the documents appear in PharmaPendium?

What is the Pharmacokinetic Module?

Poll

Live Demo

Q&A

Page 5: PharmaPendium - An introduction June 2012

What is PharmaPendium?

Page 6: PharmaPendium - An introduction June 2012

6

What is PharmaPendium?

First product to offer both searchable FDA approval packages and EMA EPARs

• 1.9M newly-searchable pages covering all of FDA history, over 70 years (from 1938),

• Searchable EMA EPAR content (from 1995)

Page 7: PharmaPendium - An introduction June 2012

7

What is PharmaPendium?

First product to offer both searchable FDA approval packages and EMA EPARs

• 1.9M newly-searchable pages covering all of FDA history, over 70 years (from 1938),

• Searchable EMA EPAR content (from 1995)

Used primarily for Preclinical assessment (Safety, PK, Efficacy) and Regulatory Affairs

Page 8: PharmaPendium - An introduction June 2012

8

What is PharmaPendium?

First product to offer both searchable FDA approval packages and EMA EPARs

• 1.9M newly-searchable pages covering all of FDA history, over 70 years (from 1938),

• Searchable EMA EPAR content (from 1995)

Used primarily for Preclinical assessment (Safety, PK, Efficacy) and Regulatory Affairs

AERS (post-marketing events)

Page 9: PharmaPendium - An introduction June 2012

9

What is PharmaPendium?

First product to offer both searchable FDA approval packages and EMA EPARs

• 1.9M newly-searchable pages covering all of FDA history, over 70 years (from 1938),

• Searchable EMA EPAR content (from 1995)

Used primarily for Preclinical assessment (Safety, PK, Efficacy) and Regulatory Affairs

AERS (post-marketing events)

Unique Content

Page 10: PharmaPendium - An introduction June 2012

10

What is PharmaPendium?

First product to bring together preclinical, clinical & post marketing data

•Normalized terminology on searches, extracted data•Which experimental data translates, why or why not?

Page 11: PharmaPendium - An introduction June 2012

11

What is PharmaPendium?

First product to bring together preclinical, clinical & post marketing data

•Normalized terminology on searches, extracted data•Which experimental data translates, why or why not?

Over 1,100,000 extracted drug safety observations•Normalized AE/Tox terminology mapped to Class, Target, Structural Chemistry

Page 12: PharmaPendium - An introduction June 2012

12

What is PharmaPendium?

First product to bring together preclinical, clinical & post marketing data

•Normalized terminology on searches, extracted data•Which experimental data translates, why or why not?

Over 1,100,000 extracted drug safety observations•Normalized AE/Tox terminology mapped to Class, Target, Structural Chemistry

Over 1,300,000 extracted PK parameter data, preclinical and clinical. Normalized and related the same way (structure, class, target)

Page 13: PharmaPendium - An introduction June 2012

13

What is PharmaPendium?

First product to bring together preclinical, clinical & post marketing data

•Normalized terminology on searches, extracted data•Which experimental data translates, why or why not?

Over 1,100,000 extracted drug safety observations•Normalized AE/Tox terminology mapped to Class, Target, Structural Chemistry

Over 1,300,000 extracted PK parameter data, preclinical and clinical. Normalized and related the same way (structure, class, target)

Extracted Data

Page 14: PharmaPendium - An introduction June 2012

How do the documents appear in PharmaPendium?

Page 15: PharmaPendium - An introduction June 2012

15

FDA Approval Packages:Examples of original documents

Page 16: PharmaPendium - An introduction June 2012

16

FDA Approval PackageSearch result

Page 17: PharmaPendium - An introduction June 2012

What is the Pharmacokinetic Module?

Page 18: PharmaPendium - An introduction June 2012

Pharmacokinetic Module

Unprecedented access to Preclinical and Clinical exposure data extracted from FDA packages (current & historic) and EMEA documents.

Page 19: PharmaPendium - An introduction June 2012

Pharmacokinetic Module

Unprecedented access to Preclinical and Clinical exposure data extracted from FDA packages (current & historic) and EMEA documents.

• preclinical and clinical exposure data at multiple parameters and usually under various experimental conditions:

Page 20: PharmaPendium - An introduction June 2012

Pharmacokinetic Module

Unprecedented access to Preclinical and Clinical exposure data extracted from FDA packages (current & historic) and EMEA documents.

• preclinical and clinical exposure data at multiple parameters and usually under various experimental conditions:

• Concomitant drugs, disease states, demographic differences, etc.

Page 21: PharmaPendium - An introduction June 2012

Pharmacokinetic Module

Unprecedented access to Preclinical and Clinical exposure data extracted from FDA packages (current & historic) and EMEA documents.

• preclinical and clinical exposure data at multiple parameters and usually under various experimental conditions:

• Concomitant drugs, disease states, demographic differences, etc.

• The level of PK data to be contained in this database is almost never published (competitive reasons) at this level of detail.

Page 22: PharmaPendium - An introduction June 2012

Pharmacokinetic Module

Unprecedented access to Preclinical and Clinical exposure data extracted from FDA packages (current & historic) and EMEA documents.

• preclinical and clinical exposure data at multiple parameters and usually under various experimental conditions:

• Concomitant drugs, disease states, demographic differences, etc.

• The level of PK data to be contained in this database is almost never published (competitive reasons) at this level of detail.

Pharmacokinetics, preclinical and clinical, & Drug Safety databases browsable within the same platform.

Page 23: PharmaPendium - An introduction June 2012

23

POLL

The poll should appear on your screen shortly….

Page 24: PharmaPendium - An introduction June 2012

24

Let’s take a look at PharmaPendium

….by going to www.pharmapendium.com

Page 25: PharmaPendium - An introduction June 2012

Questions & Answers

Page 26: PharmaPendium - An introduction June 2012

Q&A will be sent to you by e-mail.

For more information and questions please contact [email protected]

The next PharmaPendium webinar will on the 29th of May and will focus on Pharmacokinetics.

Go to www.trainingdesk.elsevier.com/pharmapendium for all training related materials.

Please fill out the survey that appears on your screen after

leaving the webinar.

Please fill out the survey that appears on your screen after

leaving the webinar.